Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Garima

      Articles By : Garima

      Novartis to pump up cardio business with Ionis deal worth Rs 15 crore

      Novartis to pump up cardio business with Ionis deal worth Rs 15 crore

      Garima27 Feb 2019 9:15 AM IST
      ZURICH: Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster...
      General Electric sells biopharma business to Danaher for Rs 2.14 crore

      General Electric sells biopharma business to Danaher for Rs 2.14 crore

      Garima27 Feb 2019 9:00 AM IST
      The biopharma business, part of its life sciences unit, generated revenue of about $3 billion in 2018. It makes instruments and software that support...
      Roche to buy Spark Therapeutics in Rs 430 crore deal

      Roche to buy Spark Therapeutics in Rs 430 crore deal

      Garima26 Feb 2019 9:30 AM IST
      Roche will acquire U.S.-based Spark for $114.50 per share, a premium of about 122 per cent to Spark's closing price on Feb. 22, the Swiss company said...
      Sanofi, Regeneron loses patent challenge to Amgen cholesterol drug Repatha

      Sanofi, Regeneron loses patent challenge to Amgen cholesterol drug Repatha

      Garima26 Feb 2019 9:05 AM IST
      Sanofi and Regeneron had stipulated that if the two Amgen patents were valid, their jointly developed cholesterol drug Praluent infringed them.U.S:...
      Desi AI based healthtech startup NIRAMAI raises Rs 42.6 Crore in Series A Funding

      Desi AI based healthtech startup NIRAMAI raises Rs 42.6 Crore in Series A Funding

      Garima25 Feb 2019 4:04 PM IST
      Bengaluru: Artificial intelligence based health tech startup NIRAMAI Health Analytics, has announced that it has closed $6 mn in a Series A round of...
      AHPI inks MoU with AiMeD to promote Indian Medical Devices Industry

      AHPI inks MoU with AiMeD to promote Indian Medical Devices Industry

      Garima25 Feb 2019 1:06 PM IST
      Hyderabad: Association of Healthcare Providers of India (AHPI) and Association of Indian Medical Device Industry (AiMeD) on Saturday signed a...
      Novartis gene therapy for SMA to be cost effective up to $900000: US group

      Novartis gene therapy for SMA to be cost effective up to $900000: US group

      Garima24 Feb 2019 9:30 AM IST
      Novartis has said the price will be determined in negotiations with health plans, but it believes the gene therapy would be cost-effective at $4...
      Activist targets Bristol Myers in drug M&A trials

      Activist targets Bristol Myers in drug M&A trials

      Garima24 Feb 2019 9:15 AM IST
      The poor performance of Bristol Myers shares and its agreement to buy troubled Celgene for $74 billion may explain Starboard's interest.NEW YORK:...
      North Dakotas first medical marijuana dispensary set to open

      North Dakotas first medical marijuana dispensary set to open

      Garima24 Feb 2019 9:15 AM IST
      The dispensary first will need to undergo what amounts to a final state inspection to ensure it meets all security rules, according to state Medical...
      Catalyst Pharma defends $375000 drug price after Bernie Sanders rebuke

      Catalyst Pharma defends $375000 drug price after Bernie Sanders rebuke

      Garima23 Feb 2019 9:15 AM IST
      Catalyst Pharma bought the U.S. rights to the drug in 2012 and got approval to sell it in the US in November last year.New York: Catalyst...
      ORDI to raise fund for rare disease patients via Race for 7

      ORDI to raise fund for rare disease patients via Race for 7

      Garima23 Feb 2019 9:05 AM IST
      Mumbai: In a move to unroll awareness for rare disease, which is not so rare, the Organization for Rare Diseases India (ORDI) has announced ‘Race for...
      ResMed, Fisher & Paykel settles global patent disputes

      ResMed, Fisher & Paykel settles global patent disputes

      Garima23 Feb 2019 9:00 AM IST
      In a joint statement, both medical device makers, ResMed and Fisher & Paykel agreed to end all ongoing infringement cases and said that under the...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok